MX2014000871A - Moduladores adrenergicos alfa-2 para el tratamiento de trastornos visuales mediados por proyecciones visuales centrales desde el ojo. - Google Patents

Moduladores adrenergicos alfa-2 para el tratamiento de trastornos visuales mediados por proyecciones visuales centrales desde el ojo.

Info

Publication number
MX2014000871A
MX2014000871A MX2014000871A MX2014000871A MX2014000871A MX 2014000871 A MX2014000871 A MX 2014000871A MX 2014000871 A MX2014000871 A MX 2014000871A MX 2014000871 A MX2014000871 A MX 2014000871A MX 2014000871 A MX2014000871 A MX 2014000871A
Authority
MX
Mexico
Prior art keywords
alpha
visual
eye
disorders mediated
treating
Prior art date
Application number
MX2014000871A
Other languages
English (en)
Inventor
John E Donello
Daniel W Gil
Ursula V Staubli
Alan C Foster
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2014000871A publication Critical patent/MX2014000871A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método para el tratamiento de transtornos visulaes mediados por el núcleo geniculado lateral, el colículo superior y la corteza visual mediante la administración, a un paciente en necesidad de tal tratamiento, de compuestos que actúan en los receptores adrenérgicos alfa 2.
MX2014000871A 2011-07-22 2012-07-17 Moduladores adrenergicos alfa-2 para el tratamiento de trastornos visuales mediados por proyecciones visuales centrales desde el ojo. MX2014000871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161510521P 2011-07-22 2011-07-22
PCT/US2012/047064 WO2013016073A1 (en) 2011-07-22 2012-07-17 Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye

Publications (1)

Publication Number Publication Date
MX2014000871A true MX2014000871A (es) 2014-06-23

Family

ID=46551952

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000871A MX2014000871A (es) 2011-07-22 2012-07-17 Moduladores adrenergicos alfa-2 para el tratamiento de trastornos visuales mediados por proyecciones visuales centrales desde el ojo.

Country Status (11)

Country Link
US (1) US20130023573A1 (es)
EP (1) EP2734200A1 (es)
JP (1) JP2014521643A (es)
CN (1) CN103826628A (es)
AU (1) AU2012287243A1 (es)
BR (1) BR112014001501A2 (es)
CA (1) CA2842866A1 (es)
IL (1) IL230581A0 (es)
MX (1) MX2014000871A (es)
RU (1) RU2014105894A (es)
WO (1) WO2013016073A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116186A1 (en) * 2012-01-30 2013-08-08 Allergan, Inc. Brimonidine for treating visual disorders mediated by central visual projections from the eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
DK3566703T3 (da) 2009-02-13 2021-07-05 Allergan Inc Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
BR112012018154A2 (pt) * 2010-01-21 2016-04-05 Allergan Inc agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular
US8501796B2 (en) * 2010-09-16 2013-08-06 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure

Also Published As

Publication number Publication date
CN103826628A (zh) 2014-05-28
BR112014001501A2 (pt) 2017-02-14
AU2012287243A1 (en) 2014-02-20
CA2842866A1 (en) 2013-01-31
JP2014521643A (ja) 2014-08-28
EP2734200A1 (en) 2014-05-28
RU2014105894A (ru) 2015-08-27
WO2013016073A1 (en) 2013-01-31
IL230581A0 (en) 2014-03-31
US20130023573A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
HK1258231A1 (zh) 治療阿爾茨海默氏症、亨廷頓氏症、孤獨症和其他障礙的方法
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX356865B (es) Nuevas soluciones terapéuticas para tratar la enfermedad de parkinson.
EA201500019A1 (ru) Способ лечения gd2-положительного рака
EA201200686A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера
UA113856C2 (xx) Злитий білок для лікування порушень метаболізму
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
MX350378B (es) Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica.
MX2013014978A (es) Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia.
MX2013006056A (es) Metodos para diagnosticar y tratar trastornos relacionados con la longitud del ojo.
WO2013061161A3 (en) New combination therapies for treating neurological disorders
MY194587A (en) Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
SG194471A1 (en) Method of treating vision disorders
MX362185B (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
MX2014013676A (es) Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia.
UA113627C2 (xx) Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування
WO2013166037A9 (en) Non-retinoid antagonists for treatment of eye disorders
AR092103A1 (es) Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1)
EA201290603A1 (ru) Способ лечения
EA201691567A1 (ru) Способы лечения легких травм головного мозга
CL2012002852A1 (es) Metodo de tratamiento de la enfermedad de alzheimer midiendo el indice de agrandamiento ventricular en el cerebro usando inmunoglobulina intravenosa como agente terapeutico.
WO2013039956A3 (en) Compositions and methods for treating mood disorders
EP2542085A4 (en) COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER

Legal Events

Date Code Title Description
FA Abandonment or withdrawal